Faculty

Cancer specialists from the Masonic Cancer Center, University of Minnesota, have launched a Phase 1 clinical trial designed to assess the toxicity of Minnelide, a University of Minnesota-developed drug that has successfully disrupted pancreatic cancer development in laboratory tests.  

Surrounded by beeping, bustling, monitors and machines that help a patient breathe; the intensive care unit (ICU) at a hospital isn’t exactly what you would call a stress-free environment. 

This summer you might be planning to get outside and partake in a variety of fun activities. But whether you’re planning to hike, play bocce ball or just relax in the water, it’s important that you stay safe and stay hydrated.

The rise of social media is changing the way we interact, get our news and even conduct business. But the rise in this connectivity has also boosted concerns for teens, including bullying and negative body images.

Try to imagine a pain so excruciating that some patients have even told physicians they’d contemplated ending their life to alleviate the suffering. Sadly, this is the type of pain characteristic of trigeminal neuralgia (TN).

It’s a sad time for the University of Minnesota community this week. John Ohlfest, Ph.D., a researcher with the Masonic Cancer Center, University of Minnesota, and first recipient of the Hedberg Family/Children’s Cancer Research Fund Endowed Chair in Brain Tumor Research, passed away on Monday, January 21, 2013, after a battle with malignant melanoma.

All, many of you have commented on this post seeking an update for human trials of Minnelide.

Pages